Compare CRNX & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | GEO |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 2018 | 1996 |
| Metric | CRNX | GEO |
|---|---|---|
| Price | $83.73 | $30.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $76.75 | $39.67 |
| AVG Volume (30 Days) | ★ 6.8M | 1.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 727.27 |
| EPS | N/A | ★ 0.29 |
| Revenue | $1,039,000.00 | ★ $2,263,420,000.00 |
| Revenue This Year | $720.10 | $13.74 |
| Revenue Next Year | $184.67 | $9.99 |
| P/E Ratio | ★ N/A | $107.52 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $25.83 | $12.51 |
| 52 Week High | $84.00 | $32.25 |
| Indicator | CRNX | GEO |
|---|---|---|
| Relative Strength Index (RSI) | 92.07 | 62.29 |
| Support Level | $33.50 | $28.74 |
| Resistance Level | N/A | $32.25 |
| Average True Range (ATR) | 0.18 | 0.98 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 53.51 | 64.11 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.